

with bipolar II disorder (BDII; 49.8 ± 13.8 years) who were followed at the hospitals or clinics participating in this study. Their age at onset was 34.9 ± 13.4 years. Consensus diagnosis by at least two senior psychiatrists according to the DSM-IV criteria was made for each patient using a nonstructured interview and by reviewing medical records. The 222 unrelated control subjects (117 women and 105 men, 30.2 ± 8.3 years old) were recruited from hospital staff and students. Control subjects were not assessed for psychiatric symptoms by any structured interview method, but they showed good social functioning and reported themselves to be in good health. All the subjects were Japanese with characteristics as described previously (Washizuka et al 2003). The objective of this study was clearly explained, and written informed consent was obtained from all subjects.

Genomic DNA was extracted from leukocytes using standard methods. There was no evidence for the presence of population substructure in either control subjects or BD using the method of Prichard (2000; Kakiuchi et al 2003). The ethics committees of the Brain Science Institute and participating institutes approved this study.

NIMH Genetics Initiative Pedigrees

For TDT, 105 trio samples (94 trios with BDI probands and 11 trios with BDII probands) were obtained from NIMH Genetics Initiative Bipolar Pedigrees. Each trio was obtained from a larger NIMH family independent of each other. Of those, results of genotyping were inconsistent with the parent-child relationship in one pedigree with BDI. Thus, this pedigree was omitted from the analysis.

Mutation Screening of the *NDUFV2* Gene by Sequencing

Polymorphisms of the upstream region of the *NDUFV2* (GenBank accession number NT_010859) were screened in 20 randomly selected Japanese subjects (9 BDI, 3 BDII, and 8 control subjects). For the scanning of the 5'-upstream region, the following primer sets were used: 5'-TATAGGTCATGAACTCAAAAAGACG and 5'-GCCACACTGTTACCTTCC. These primers amplified a 3983bp product. Polymerase chain reaction (PCR) was performed in a 25-µL volume containing 20 ng of genomic DNA, .2 µmol/L of each primer, 100 µmol/L of each dNTP, 12.5 µL of 2 × GC buffer I (Takara, Shiga, Japan), and 1.25 units of LA-Taq DNA polymerase (Takara). After an initial denaturation at 95°C for 2 min, 27 cycles consisting of 30 sec at 94°C, 30 sec at 62°C, and 4 min at 72°C were performed. An extension at 72°C for 5 min followed. Sequencing of the PCR products was conducted using the BigDye terminator sequencing kit (Applied Biosystems, Foster City, California) and an ABI 3700 DNA sequencer (Applied Biosystems). For this analysis, 15 sequence primers were used.

Genotyping

Five single nucleotide polymorphisms (SNPs) detected in the screening analysis, -3542G> A, -3245T> C, -3041T> G, -2694A> G, and -1020G> T, were genotyped in Japanese samples and NIMH bipolar pedigrees. For genotyping of the former four polymorphisms, genomic DNA was amplified by using the upstream primer 5'-AAACTAGCCCTTCCATTCTCCTT and the downstream primer 5'-CCTTCTTGCTCATTGGCT-TACA. These primers amplified a 1547bp product. We performed PCR in a 15-µL volume containing 15 ng of genomic DNA, .1 µmol/L of each primer, 25 µmol/L of each dNTP, 1.5 µL of 10 × Ex-Taq buffer (Takara), and .72 units of Ex-Taq DNA polymerase (Takara). After an initial denaturation at 95°C for 2 min, 35 cycles

Table 1. Pairwise Linkage Disequilibrium Between Polymorphisms in the *NDUFV2*

	-3542G>A	-3245T>C	-3041T>G	-2694A>G	-1020G>T	-796C>G	-795T>G	-602G>A	-233T>C	86C>T
-3542G>A	.32									<i>r</i> ² = .59
-3245T>C	.32	<i>r</i> ² = .97							<i>r</i> ² = .20	<i>r</i> ² = .59
-3041T>G	.28	<i>r</i> ² = .16	<i>r</i> ² = .17						<i>r</i> ² = .16	<i>r</i> ² = .21
-2694A>G	.32	<i>r</i> ² = .93	<i>r</i> ² = .17	<i>r</i> ² = .97					<i>r</i> ² = .08	<i>r</i> ² = .60
-1020G>T	.16	<i>r</i> ² = 1.00	<i>r</i> ² = .17	<i>r</i> ² = .17	<i>r</i> ² = .11				<i>r</i> ² = .21	<i>r</i> ² < .01
-796C>G	.41	<i>r</i> ² = 1.00	<i>r</i> ² = .94	<i>r</i> ² = .97	<i>r</i> ² = 1.00	<i>r</i> ² = .29			<i>r</i> ² = .04	<i>r</i> ² = .16
-795T>G	.41	<i>r</i> ² = .96	<i>r</i> ² = .94	<i>r</i> ² = .97	<i>r</i> ² = 1.00	<i>r</i> ² = .21	<i>r</i> ² = 1.00		<i>r</i> ² = .43	<i>r</i> ² = .16
-602G>A	.32	<i>r</i> ² = .81	<i>r</i> ² = .77	<i>r</i> ² = .98	<i>r</i> ² = .92	<i>r</i> ² = .78	<i>r</i> ² = .86	<i>r</i> ² = .21	<i>r</i> ² = .13	<i>r</i> ² = .56
-233T>C	.28	<i>r</i> ² = .84	<i>r</i> ² = .65	<i>r</i> ² = 1.00	<i>r</i> ² = .29	<i>r</i> ² = .86	<i>r</i> ² = .83	<i>r</i> ² = .83	<i>r</i> ² = .83	<i>r</i> ² = .27
86C>T	.39	<i>r</i> ² = .87	<i>r</i> ² = 1.00	<i>r</i> ² = .87	<i>r</i> ² < .01	<i>r</i> ² = .59	<i>r</i> ² = .59	<i>r</i> ² = .83	<i>r</i> ² = 1.00	<i>r</i> ² = .27

Table 2. Genotypic and Allele Distributions of the Additional *NDUFV2* Gene Polymorphisms and –602G>A in Japanese Controls and Bipolar Patients

Polymorphisms		Subject Counts (%)				p Value ^b
		Controls	BP Total	BPI	BPII	
–3542G>A						
Genotype	G/G	15 (.07)	25 (.13)	13 (.09)	12 (.23)	
	G/A	102 (.46)	80 (.42)	63 (.46)	17 (.32)	
	A/A	104 (.47)	85 (.45)	61 (.45)	24 (.45)	
P Value			.09	.62	.003	
Allele	G	132 (.30)	130 (.34)	89 (.32)	41 (.39)	.21
	A	310 (.70)	250 (.66)	185 (.68)	65 (.61)	
P Value			.20	.50	.08	
–3245T>C						
Genotype	T/T	15 (.07)	24 (.13)	12 (.09)	12 (.23)	
	T/C	101 (.47)	80 (.42)	64 (.47)	16 (.30)	
	C/C	97 (.46)	84 (.45)	59 (.44)	25 (.47)	
P Value			.14	.80	.002	
Allele	T	131 (.31)	128 (.34)	88 (.33)	40 (.38)	.38
	C	295 (.69)	248 (.66)	182 (.67)	66 (.62)	
P Value			.32	.61	.20	
–3041T>G						
Genotype	T/T	106 (.49)	98 (.52)	73 (.54)	25 (.47)	
	T/G	88 (.40)	86 (.46)	60 (.44)	26 (.49)	
	G/G	23 (.11)	4 (.02)	2 (.02)	2 (.04)	
P Value			.001	.002	.23	
Allele	T	300 (.69)	282 (.75)	206 (.76)	76 (.72)	.12
	G	134 (.31)	94 (.25)	64 (.24)	30 (.28)	
P Value			.07	.04	.63	
–2694A>G						
Genotype	A/A	16 (.07)	24 (.13)	12 (.09)	12 (.23)	
	A/G	99 (.46)	79 (.42)	62 (.46)	17 (.32)	
	G/G	100 (.47)	84 (.45)	60 (.45)	24 (.45)	
P Value			.19	.86	.006	
Allele	A	131 (.31)	128 (.34)	88 (.33)	40 (.38)	.38
	G	295 (.69)	248 (.66)	182 (.67)	66 (.62)	
P Value			.32	.61	.20	
–1020G>T						
Genotype	G/G	160 (.72)	131 (.69)	93 (.66)	38 (.72)	
	G/T	58 (.26)	52 (.28)	39 (.29)	13 (.25)	
	T/T	4 (.02)	6 (.03)	4 (.03)	2 (.03)	
P Value			.64	.62	.60	
Allele	G	378 (.85)	314 (.83)	225 (.83)	89 (.84)	.66
	T	66 (.15)	64 (.17)	47 (.17)	17 (.16)	
P Value			.44	.39	.76	
–602G>A^a						
Genotype	G/G	17 (.08)	27 (.14)	15 (.11)	12 (.23)	
	G/A	106 (.48)	77 (.41)	60 (.44)	17 (.32)	
	A/A	99 (.44)	85 (.45)	61 (.45)	24 (.45)	
P Value			.07	.51	.003	
Allele	G	140 (.32)	131 (.35)	90 (.33)	41 (.39)	.37
	A	304 (.68)	247 (.65)	182 (.67)	65 (.61)	
P Value			.34	.66	.15	

BP, bipolar disorder

^aData of Washizuka et al (2003).^bDifferences in genotype distributions or allele frequencies among patients with BPI, BPII, and controls.

consisting of 30 sec at 94°C, 30 sec at 61°C, and 2 min at 72°C were performed. An extension at 72°C for 3 min followed.

For genotyping of the –1020G>T polymorphism, the primer sets were used as follows: 5'-ACCAAGGCATTTGGTATCTATTCT and 5'-ATGTTTGGTTATCTCTGGAAA. We performed PCR in a 25- μ L volume containing 25 ng of genomic DNA, .1 μ mol/L of each primer, 25 μ mol/L of each dNTP, 2.5 μ L of 10 \times Ex-Taq buffer, and 1.2 units of Ex-Taq DNA polymerase. After an initial

denaturation at 95°C for 2 min, 35 cycles consisting of 20 sec at 94°C, 30 sec at 60°C, and 30 sec at 72°C were performed. An extension at 72°C for 3 min followed.

In addition, our previously reported polymorphisms of the *NDUFV2* gene (–796C>G, –795T>G, –602G>A, –233T>C, and 86C>T) were also genotyped in NIMH samples. The primer set and the PCR condition that were used in genotyping of these SNPs are shown in our previous article (Washizuka et al 2003).




Figure 1. Haplotype associations in Japanese case control samples: (a) three-marker haplotype analysis; (b) two-marker haplotype analysis. *P* value indicates the global *P* analyzed using COCAPHASE program. Gray squares indicate statistically significant global *p* value.

Sequencing of the PCR products was conducted using the BigDye terminator sequencing kit (Applied Biosystems) and an ABI 3700 DNA sequencer (Applied Biosystems).

Statistical Procedures

Deviations from Hardy–Weinberg equilibrium (HWE) were evaluated by use of the Arlequin program (<http://anthropologie.unige.ch/arlequin/methods.html>). Genotype distributions and allele frequencies between patients and control subjects were computed using Fisher's Exact Probability Test, which was applied using SPSS software (SPSS, Tokyo, Japan). For other analyses, UNPHASED programs (COCAPHASE and TDTPHASE; <http://www.rfcgr.mrc.ac.uk/~fdudbrid/software/unphased/>) were used. The normalized LD coefficient *D'* and the squared correlation coefficient *r*² were calculated using COCAPHASE program. For TDT of NIMH trio samples, the McNemar Test was used. For the computation of haplotype frequencies, evaluation of haplotypic distributions, and TDT analysis of the multimarker haplotypes, the COCAPHASE and TDTPHASE programs were used. To evaluate the data appropriately, we reanalyzed the significant result using the permutation test implemented in COCAPHASE and TDTPHASE. Sequences were searched for potential transcription factor binding sites using the Match program (<http://www.gene-regulation.de/>).

Promoter Assay

A 1106-bp fragment (–1111 to –6) of the upstream from the initiation codon of the *NDUFV2* gene was amplified by PCR and cloned into the *MluI/BglII* site of pGL3-Basic vector (Promega, Madison, Wisconsin). Two kinds of reporter plasmids, having either –602G or –602A were prepared. A 586-bp fragment (–591 to –6) lacking the –602G>A site was also amplified and cloned into the same vector. HeLa-S3 and HEK293 cells cultured in a 96-well plate were transfected using Superfect (Qiagen, Valencia, California) with .5 mg of the reporter plasmid, .05 mg of a reference plasmid (pRL-TK), and the pGL3-Basic vector carrying no insert. After 36 hours incubation, luciferase activities were measured with the aid of Dual-Glo luciferase assay system (Promega). Four independent experiments were performed for each condition, and the mean and SEM values were presented.

Results

We previously reported that –602G>A, among four polymorphisms (–796C>G, –795T>G, –602G>A, –233T>C) in




Figure 2. Promoter assay. Promoter activity of three kinds of reporter plasmids, having –602G or –602A and lacking the –602G>A site, were examined by the luciferase assay. Two kinds of cells, HeLa-S3 and HEK293, were used. Four independent experiments were performed for each condition, and the mean and SEM values were presented. The transcription activity of the –602G construct was significantly higher than that of the –602A in both HeLa-S3 and HEK293. The short construct lacking in the –602G>A site presented nearly equal activity of the –602A construct and had significantly smaller activity compared with –602G constructs. ***p* < .01. **p* < .05. + *p* = .05.

the upstream region of *NDUFV2*, showed the significant association with BD (Washizuka et al 2003). In this study, four novel (–3542G>A, –3245T>C, –3041T>G, –2694A>G) and one known (–1020G>T) polymorphisms were detected by sequencing the upstream region extending up to 3963 bp of the transcription initiation site in the *NDUFV2*. We then genotyped these polymorphisms in Japanese patients with BD (*n* = 189) and control subjects (*n* = 222). The genotype frequencies of these five polymorphisms were in HWE in control subjects, although –3041T>C polymorphism was not in BDI patients, and –3245T>G was not in BDII patients. There was no significant difference of genotype frequencies of each SNP between male and female subjects. Detected polymorphisms in this study and in our previously reported polymorphisms (–796C>G, –795T>G, –602G>A, –233T>C, and 86C>T) were in strong linkage disequilibrium with each other (Table 1).

The genotype and allele distributions of the polymorphisms in Japanese population are shown in Table 2. The data for –602G>A polymorphism were cited from our previous paper (Washizuka et al 2003). Statistically significant differences in genotype distribution were observed between patients with BD and control subjects for –3041T>G (*p* = .001). The –3542G>A, –3245T>G, and –2694A>G polymorphisms showed significant genotypic association with BDII (*p* = .003, *p* = .002, and *p* = .006, respectively). These SNPs tended to be associated with BD or BDII even after Bonferroni correction. There was also a nominally significant difference in allelic distribution of –3041T>G polymorphism between patients with BDI and control subjects (*p* = .04).

Haplotype analysis consisting of all 10 polymorphisms revealed a statistically significant association in Japanese samples (global *p* < .0001). To explore which part of the *NDUFV2* gene

Table 3. Estimated Haplotype Frequencies of *NDUFV2* in Japanese Analyzed by Using the COCAPHASE Program

Haplotype ^a	Case	Frequency	Control	Frequency	χ^2	P Value	Common
A-A	244	.64	270	.61	.34	.55	+
G-A	3	.008	31	.07	20.35	<.0001	+
A-G	4	.01	37	.08	23.81	<.0001	+
G-G	127	.33	99	.22	10.79	.001	+
Global P						<.0001 (<.0001) ^b	

^aHaplotypes of -3542G>A and -602G>A.

^bThe global P value in parentheses shows the global significance by permutation test.

contributes most to this overall association, we employed the sliding window approach in which each set of two or three consecutive polymorphisms were tested for association with BD (two- or three-marker haplotype analysis). This analysis showed evidence of association with BD in two limited regions around -3542G>A and -602G>A (most significant haplotype $p < .0001$, global $p < .0001$, and most significant haplotype $p = .008$, global $p = .001$, for the three-marker analysis, and global $p < .0001$ and global $p = .002$, respectively, for the two-marker analysis; Figure 1).

Because these two SNPs were located at the putative promoter region, we supposed that these polymorphisms might alter the transcription activity. At the beginning, we prepared a 3983bp fragment containing those two polymorphisms and tried to ligate this fragment into the pGL3-basic vector; this was not successful, however. Then we examined whether the -602G>A polymorphism had functional significance. Based on our previous analysis indicating that the two major haplotypes, C-T-A-T and C-T-G-T (consisting of -796C>G, -795T>G, -602G>A, and -233T>C polymorphisms of *NDUFV2*) were associated with BD, constructs of these two haplotypes were analyzed. Promoter activity was examined in two cell lines, HeLa-S3 and HEK293. The transcription activity of the -602G construct was significantly higher than that of the -602A both in HeLa-S3 and HEK293 ($p = .03$ for HeLa-S3, and $p = .05$ for HEK293). The short construct lacking in the -602G>A site presented nearly equal activity of the -602A construct but had significantly smaller activity compared with the -602G construct ($p = .0009$ and $p = .005$, respectively; Figure 2).

Because we could not experimentally examine the functional significance of the -3542G>A, we examined whether this site affects the putative binding sites of transcription factors using the Match program. The -3542G>A was predicted to be within the putative binding site for HSF (heat shock transcription factor). HSF1 is known to affect the expression of several other nuclear encoded mitochondrial complex I subunit genes (e.g., *NDUFB8*,

NDUFA10, *NDUFAB1*, and *NDUFSL1*). Recently, the binding sequence of HSF1 was well characterized (TTCTTC||G/A|GAANNNTTC|T/C|); the bases similar to this site of *NDUFV2* promoter was italicized; Trinklein et al 2004). When the -3542 site is G, the core sequence of putative binding site for HSF1, GAA, is lost, and probability of binding was predicted to be decreased.

Thus, the frequency of haplotypes consisting of -3542G>A and -602G>A polymorphisms was also estimated. Distributions of haplotype frequencies differed significantly between patients with BD and control subjects (global $p < .0001$) (Table 3). Among the haplotypes, the G-G haplotype was significantly more frequently seen in BD ($p = .001$), whereas G-A and A-G haplotypes were significantly less common in patients with BD compared with control subjects ($p < .0001$). The results were basically similar when younger control subjects were excluded to match ages of the subjects.

We then performed a TDT in NIMH Genetics Initiative Bipolar Pedigrees. The distributions of genotypes of all 10 detected polymorphisms of the probands, fathers, and mothers were in HWE. We could not detect any allele that was significantly overtransmitted from patients to affected offspring in the NIMH trio samples of BD (Table 4).

We then examined the transmission of haplotypes consisting of -3542G>A and -602G>A polymorphisms from patients to affected offspring by using TDTPHASE program. We found significant association of the *NDUFV2* haplotypes with BD (global $p < .0001$). Two haplotypes (G-A and A-G) tended to be undertransmitted in parents-proband trios of NIMH samples (nominal $p = .04$ and $p = .01$, respectively; Table 5).

Discussion

We identified four novel polymorphisms (-3542G>A, -3245T>C, -3041T>C, and -2694A>G) associated with BD in this study. Haplotype analysis revealed that two haplotype blocks surrounding the -3542G>A and -602G>A polymor-

Table 4. Transmission Disequilibrium Test in National Institute of Mental Health Initiative Bipolar Pedigrees

Polymorphism	Allele	Tr	Not Tr	Ratio	χ^2	P	Number of Trios
-3542G>A	G	20	27	.74	1.04	.30	85
-3245T>C	T	20	30	.67	2.00	.15	91
-3041T>G	T	39	44	.89	.30	.58	90
-2694A>G	A	19	26	.73	1.08	.29	81
-1020G>T	G	10	16	.63	1.38	.23	95
-796C>G	C	42	48	.88	.40	.52	94
-602G>A	G	31	24	1.29	.89	.34	98
-233T>C	T	43	50	.86	.52	.46	99
86C>T	C	34	25	1.36	1.37	.24	99

Tr, transmitted.

Table 5. Transmission of Haplotypes in National Institute of Mental Health Initiative Bipolar Pedigrees Analyzed by using TDTPHASE

Haplotype ^a	Tr	Frequency	Not Tr	Frequency	χ^2	P Value	Common
A-A	146	.84	137	.80	1.61	.20	+
G-A	<.01	<.01	3	.02	4.18	.04	+
A-G	<.01	<.01	4	.02	5.59	.01	+
G-G	26	.15	28	.16	.08	.76	+
Global P						.01 (.11) ^b	

^aHaplotypes of -3542G>A and -602G>A.

^bThe global P value in parentheses shows the global significance by permutation test.

phisms were associated with BD. The haplotype of these two SNPs were significantly associated with BD in Japanese subjects. In NIMH trios, no individual SNP was associated, and the overtransmission of the risk haplotype in Japanese, G-G, was not observed. Although the observed trend of undertransmission of two haplotypes, G-A and A-G, might be due to the small number of trios, it is noteworthy that the trends of undertransmission of these two haplotypes seen in the NIMH bipolar trio samples were in the same direction to the significant decrease of these haplotypes in Japanese BD subjects.

Although the mechanism by which -602A>G changed the promoter activity is unknown, it would be of interest to note that the -602G polymorphism loses the putative binding site of a transcription factor, p300 (CCACTC). The finding that the -602G haplotype is more common in BD, although yielding a significantly higher promoter activity, is apparently inconsistent with our mitochondrial dysfunction hypothesis in BD; however, the direction of change of promoter activity in the luciferase assay cannot be directly compared with that in vivo. First, promoter activity can be affected by neighboring sequences because several transcription factors form a complex. When only a part of the promoter sequence is subcloned into the luciferase vector, as in this study, the promoter activity does not directly represent the activity in vivo. Second, regulation of gene expression is complex. Although we reported that mRNA expression of *NDUFV2* was decreased in the lymphoblastoid cells, Karry et al (2004) reported that the protein encoded by *NDUFV2* was up-regulated in autopsied BD brains. Thus, it cannot be concluded what kind of mitochondrial dysfunction is caused by polymorphisms of *NDUFV2* promoter. Even though the direction of the change may not represent the promoter activity in vivo, the results of promoter assay indicate that this region has some functional activity only when the -602 position is G.

We could not determine whether -3542G>A affects promoter activity, and this would be a worthwhile topic for future study. Because it has been reported that lithium enhances HSF1 activity (Carmichael et al 2002), it would be particularly interesting to examine the effects of HSF1.

It is most important to test whether the association of *NDUFV2* with BD is replicated using independent BD case-control or trio samples. In addition, 18p11 is a common linkage locus for BD and schizophrenia (Berrettini 2000; Lewis et al 2003), and mRNA and protein expression of *NDUFV2* is also altered in schizophrenia (Karry et al 2004). It would thus be interesting to examine the association between *NDUFV2* and schizophrenia.

In conclusion, the haplotypes consisting of -3542G>A and -602G>A polymorphisms in the upstream region of *NDUFV2* were associated with BD commonly in two ethnicities. Together with altered promoter activity, these findings indicate the role of *NDUFV2* as a genetic risk factor of bipolar disorder.

Data and biomaterials of the National Institute of Mental Health (NIMH) pedigrees were collected in four projects that participated in the NIMH Bipolar Disorder Genetics Initiative. From 1991 to 1998, the principal investigators and co-investigators were as follows: Indiana University, Indianapolis, Indiana, U01 MH46282, John Nurnberger, M.D., Ph.D., Marvin Miller, M.D., and Elizabeth Bowman, M.D.; Washington University, St. Louis, MO, U01 MH46280, Theodore Reich, M.D., Allison Goate, Ph.D., and John Rice, Ph.D.; Johns Hopkins University, Baltimore, Maryland U01 MH46274, J. Raymond DePaulo, Jr., M.D., Sylvia Simpson, M.D., MPH, and Colin Stine, Ph.D.; NIMH Intramural Research Program, Clinical Neurogenetics Branch, Bethesda, Maryland, Elliot Gershon, M.D., Diane Kazuba, B.A., and Elizabeth Maxwell, M.S.W.

- Berrettini WH (2000): Susceptibility loci for bipolar disorder: Overlap with inherited vulnerability to schizophrenia. *Biol Psychiatry* 47:245–251.
- Berrettini WH, Ferraro TN, Goldin LR, Detera-Wadleigh SD, Choi H, Muniec D, et al (1997): A linkage study of bipolar illness. *Arch Gen Psychiatry* 54:27–35.
- Carmichael J, Sugars KL, Bao YP, Rubinsztein DC (2002): Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. *J Biol Chem* 277:33791–33798.
- de Coo R, Buddiger P, Smeets H, Geurts van Kessel A, Morgan-Hughes J, et al (1995): Molecular cloning and characterization of the active human mitochondrial NADH: Ubiquinone oxidoreductase 24-kDa gene (*NDUFV2*) and its pseudogene. *Genomics* 26:461–466.
- Gershon ES, Bander JA, Detera-Wadleigh SD, Ferraro TN, Berrettini WH (1996): Maternal inheritance and chromosome 18 allele sharing in unilineal bipolar illness pedigrees. *Am J Med Genet* 67:202–207.
- Goodwin FK, Jamison KR (1990): *Manic-Depressive Spectrum*. New York: Oxford University Press.
- Hattori N, Suzuki H, Wang Y, Minoshima S, Shimizu N, Yoshino H, et al (1995): Structural organization and chromosomal localization of the human nuclear gene (*NDUFV2*) for the 24-kDa iron-sulfur subunit of complex I in mitochondrial respiratory chain. *Biochem Biophys Res Commun* 216:771–777.
- Kakiuchi C, Iwamoto K, Ishiwata M, Bundo M, Kasahara T, Kusumi I, et al (2003): Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder. *Nat Genet* 35:171–175.
- Karry R, Klein E, Ben Shachar D, (2004): Mitochondrial complex I subunits expression is altered in schizophrenia: A postmortem study. *Biol Psychiatry* 55:676–684.
- Kato T, Kato N (2000): Mitochondrial dysfunction in bipolar disorder. *Bipolar Disord* 2:180–190.
- Kato T, Kunugi H, Nanko S, Kato N (2001): Mitochondrial DNA polymorphisms in bipolar disorder. *J Affect Disord* 62:151–164.
- Kato T, Stine OC, McMahon FJ, Crowe RR (1997): Increased levels of a mitochondrial DNA deletion in the brain of patients with bipolar disorder. *Biol Psychiatry* 42:871–875.
- Kato T, Takahashi S, Shioiri T, Inubushi T (1993): Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo 31P and 7Li magnetic resonance spectroscopy. *J Affect Disord* 27:53–59.
- Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, et al (2003): Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. *Am J Hum Genet* 73:34–48.

- Nakatani N, Aburatani H, Nishimura K, Semba J, Yoshikawa T (2004): Comprehensive expression analysis of a rat depression model. *Pharmacogenomics J* 4:114–126.
- Nothen MM, Cichon S, Rohleder H, Hemmer S, Franzek E, Fritze J, et al (1999): Evaluation of linkage of bipolar affective disorder to chromosome 18 in a sample of 57 German families. *Mol Psychiatry* 4:76–84.
- Pritchard JK, Stephens M, Donnelly P (2000): Inference of population structure using multilocus genotype data. *Genetics* 155:945–959.
- Segurado R, Detera-Wadleigh SD, Levinson DF, Lewis CM, Gill M, Nurnberger JI, et al (2003): Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: Bipolar disorder. *Am J Hum Genet* 73:49–62.
- Smeitink J, Sengers R, Trijbels F, van den Heuvel L (2001): Human NADH: ubiquinone oxidoreductase. *J Bioenerg Biomembr* 33:259–266.
- Stine OC, Xu J, Koskela R, McMahon FJ, Gschwend M, Friddle C, et al (1995): Evidence for linkage of bipolar disorder to chromosome 18 with a parent-of-origin effect. *Am J Hum Genet* 57:1384–1394.
- Trinklein ND, Murray JI, Hartman SJ, Botstein D, Myers RM (2004): The role of heat shock transcription factor 1 in the genome-wide regulation of the mammalian heat shock response. *Mol Biol Cell* 15:1254–1261.
- Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Martin R, et al (1999): Lithium responsive bipolar disorder, unilinearity and chromosome 18: A linkage study. *Am J Med Genet* 88:411–415.
- Washizuka S, Kakiuchi C, Mori K, Kunugi H, Tajima O, Akiyama T, et al (2003): Association of mitochondrial complex I subunit gene *NDUFV2* at 18p11 with bipolar disorder. *Am J Med Genet* 120B:72–78.



Mitochondrial DNA 3644T→C mutation associated with bipolar disorder

Kae Munakata^a, Masashi Tanaka^b, Kanako Mori^a, Shinsuke Washizuka^a, Makoto Yoneda^c, Osamu Tajima^d, Tsuyoshi Akiyama^e, Shinichiro Nanko^f, Hiroshi Kunugi^g, Kazuyuki Tadokoro^g, Norio Ozaki^h, Toshiya Inada^h, Kaoru Sakamotoⁱ, Takako Fukunagaⁱ, Yoshimi Iijima^j, Nakao Iwata^k, Masahiko Tatsumi^l, Kazuo Yamada^m, Takeo Yoshikawa^m, Tadafumi Kato^{a,*}

^aLaboratory for Molecular Dynamics of Mental Disorders, RIKEN Brain Science Institute, Hirosawa 2-1, Wako, Saitama 351-0198, Japan

^bDepartment of Gene Therapy, Gifu International Institute of Biotechnology, Gifu, Japan

^cDepartment of Internal Medicine, Fukui Medical University, Fukui, Japan

^dKyorin University School of Health Sciences, Kyorin, Japan

^eDepartment of Neuropsychiatry, NTT East Kanto Medical Center, Kanto, Japan

^fDepartment of Psychiatry, Teikyo University School of Medicine, Teikyo, Japan

^gDepartment of Mental Disorder Research, National Institute of Neuroscience, Tokyo, Japan

^hDepartment of Psychiatry, Faculty of Medicine, Nagoya University, Nagoya, Japan

ⁱDepartment of Psychiatry, Tokyo Women's Medical College, Tokyo, Japan

^jNational Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan

^kDepartment of Psychiatry, Faculty of Medicine, Fujita Health University, Fujita, Japan

^lDepartment of Psychiatry, Faculty of Medicine, Showa University, Showa, Japan

^mLaboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Hirosawa 2-1, Wako, Saitama 351-0198, Japan

Received 11 June 2004; accepted 18 August 2004

Available online 17 September 2004

Abstract

Mitochondrial dysfunction associated with mutant mitochondrial DNA (mtDNA) has been suggested in bipolar disorder, and comorbidity with neurodegenerative diseases was often noted. We examined the entire sequence of mtDNA in six subjects with bipolar disorder having comorbid somatic symptoms suggestive of mitochondrial disorders and found several uncharacterized homoplasmic nonsynonymous nucleotide substitutions of mtDNA. Of these, 3644C was found in 5 of 199 patients with bipolar disorder but in none of 258 controls ($p = 0.015$). The association was significant in the extended samples [bipolar disorder, 9/630 (1.43%); controls, 1/734 (0.14%); $p = 0.007$]. On the other hand, only 5 of 25 family members with this mutation developed bipolar disorder, of which 4 patients with 3644C had comorbid physical symptoms. The 3644T→C mutation converts amino acid 113, valine, to alanine in the NADH-ubiquinone dehydrogenase subunit I, a subunit of complex I, and 113 valine is well conserved from *Drosophila* to 61 mammalian species. Using transmitochondrial cybrids, 3644T→C was shown to decrease mitochondrial membrane potential and complex I activity compared with haplogroup-matched controls. According to human mitochondrial genome polymorphism databases, 3644C was not found in centenarians but was found in 3% of patients with Alzheimer disease and 2% with Parkinson disease. The result of modest functional impairment caused by 3644T→C suggests that this mutation could increase the risk for bipolar disorder.

© 2004 Elsevier Inc. All rights reserved.

Keywords: Bipolar disorder; MtDNA 3644T→C; Association study; Mitochondrial membrane potential; Complex I activity

Bipolar disorder is a major mental disorder characterized by recurrent manic and depressive episodes affecting about 1% of the population. The contribution of multiple genetic factors in the etiology of bipolar disorder is known from studies of twins, adoptions, and families. Although recent

* Corresponding author. Fax: +81 48 467 6947.

E-mail address: kato@brain.riken.go.jp (T. Kato).

studies suggested several candidate polymorphisms, such as Val 311 of the brain-derived neurotrophic factor [1,2] and the –116G polymorphism of X-box binding protein 1 [3], the pathophysiological mechanisms of bipolar disorder have not yet been totally elucidated. Mitochondrial dysfunction in bipolar disorder was initially suggested by altered brain energy metabolism detected by ^{31}P magnetic resonance spectroscopy [4] and was recently supported by the altered gene expressions of mitochondria-related genes revealed by DNA microarray analysis in the postmortem brain [5]. The comorbidity of bipolar disorder or depression and a mitochondrial disorder, chronic-progressive external ophthalmoplegia (CPEO) [6–8], also suggests that mitochondrial dysfunction can cause bipolar disorder. It was pointed out that some families of bipolar disorder were seen in the maternal lineage [9], suggesting that mitochondrial DNA may have a pathophysiological role in bipolar disorder. The authors previously reported an association between bipolar disorder and two mitochondrial DNA (mtDNA) polymorphisms, 5178C and 10398A, in Japanese subjects [10]. A similar trend of association with 10398A was also reported in Caucasians [11]. These two polymorphisms convert amino acids in the subunits of complex I (NADH:ubiquinone oxidoreductase). NDUFV2, a nuclear-encoded complex I subunit gene, was also associated with bipolar disorder [12]. These results suggest that other genetic variations of complex I subunits in mtDNA are also risk factors for bipolar disorder.

Human mtDNA is inherited only maternally and encodes 13 protein subunits of the respiratory chain, including 7 complex I subunit genes, 22 tRNAs, and rRNAs [13]. It has been reported [14] that heteroplasmic tRNA mutations of mtDNA are related to neuromuscular diseases such as mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS), and myoclonus epilepsy with ragged-red fibers. Large-scale deletions are related to CPEO. On the other hand, there are missense mutations of mtDNA related to diseases, such as neurogenic muscle weakness, ataxia, and retinitis pigmentosa; Leigh encephalopathy; and Leber hereditary optic neuropathy (LHON). Most are heteroplasmic, a mixture of mutant and wild-type mtDNA, but sometimes these mutations can be homoplasmic in patients. The homoplasmic mutation of 1555A→G in the rRNA coding region related to inherited hearing loss caused by aminoglycoside toxicity is well described [15,16]. Alterations in mtDNA have also been studied in patients with Parkinson disease and Alzheimer disease [17,18]. The phenotypes of mitochondrial diseases are diverse and overlapping. The same mtDNA mutation can produce quite different phenotypes, while different mutations can produce similar phenotypes. The mutations or polymorphisms associated with bipolar disorder, if any, may also cause overlapping phenotypes and become a risk factor for other disorders.

In this study, we hypothesized that there are some homoplasmic mutations or polymorphisms increasing the

risk for bipolar disorder and other signs and symptoms related to mitochondrial impairment. To identify such nucleotide substitutions of mtDNA, we sequenced the entire 16.6-kb mtDNA of patients with comorbidity of bipolar disorder and somatic symptoms frequently associated with mitochondrial disorders. Among newly identified nonsynonymous nucleotide substitutions in these patients, the 3644T→C at NADH-ubiquinone dehydrogenase subunit I (ND1), decreasing mitochondrial membrane potential and complex I activity, was associated with bipolar disorder. The comorbidity with bipolar disorder was present in most of these cases but their phenotypes were various. It was suggested that this mutation could increase risks for bipolar disorder with syndromic comorbidity.

Results and discussion

Unreported homoplasmic mtDNA base substitutions in patients

We examined the entire mtDNA sequence of six patients with bipolar disorder and somatic symptoms suggestive of mitochondrial disorders, such as ptosis, optic neuropathy, cardiomyopathy, and myoclonus (Table 1). None of them could be diagnosed as known mitochondrial diseases, such as MELAS, CPEO, and LHON, because of the reasons as described under Case reports. Five of them had a family history of mood disorder compatible with maternal inheritance. Every patient had several base substitutions compared with the revised Cambridge Reference Sequence [13,19]. The average number of base substitutions in each individual was 32.5 ± 6.9 (mean \pm SD), and that of nonsynonymous base substitutions was 5.5 ± 2.1 . We consulted the MITOMAP database (<http://www.mitomap.org/>) [20,21], and two mutations were provisionally reported in relation to mitochondrial diseases, 11084A→G (MELAS) and 12311T→C (CPEO). We also found four nonsynonymous nucleotide substitutions, 3644T→C, 4705T→C, 13651A→G, and 13928G→T, which were not registered in the MITOMAP, all of which were in the complex I subunits. We confirmed that these base substitutions were homoplasmic by the PCR restriction-length polymorphism method (PCR-RFLP).

To identify the mtDNA base substitutions having pathophysiological significance, we examined whether these base substitutions were found in 96 Japanese centenarians using the mtSNP database (Human Mitochondrial Genome Polymorphism Database in Japan, http://www.giib.or.jp/mtsnp/index_e.html) [22]. We regarded the base substitutions found in centenarians as having minimum pathophysiological significance. Base substitutions 4705T→C, 11084A→G, 12311T→C, and 13651A→G were found in centenarians, while two base substitutions, 3364T→C and 13928G→T, were not found in centenarians.

Table 1
Patients and unreported nucleotide substitutions of mitochondria DNA

Case	Diagnosis	Gender	Age at onset	Clinical manifestations		MtDNA substitutions	
				Physical symptoms	Family history	Unreported	Provisionally disease related
1	Bipolar I disorder	F	17	Optic neuritis	Mo, depression	13651A→G	
2	Bipolar I disorder	M	30	Cerebral infarction	Bro, bipolar disorder		
3	Bipolar I disorder	M	50	Dilated cardiomyopathy Ptosis Epilepsy	MoSib, psychotic NOS MoSib, depression		12311T→C (CPEO)
4	Bipolar I disorder	F	24	Cardiac arrhythmia Epileptic EEG	Bro, bipolar disorder Sis, NOS		11084A→G (MELAS)
5	Bipolar I disorder	M	57	Ptosis Muscle weakness NIDDM	Sporadic	3644T→C	
6	Bipolar I disorder	M	35	Multiple cerebral infarction Ptosis	Sib, depression	4705T→C 13928G→T	

Abbreviations: Mo, mother; Bro, brother; Sis, sister; Sib, sibling; MoSib, mother's sibling; psychotic NOS, psychotic disorder not otherwise specified.

Association study of mtDNA base substitutions

To know whether these two base substitutions, 3644T→C and 13928G→T, are associated with bipolar disorder, we used two sets of the study subjects. The initial association study consisted of 199 patients with bipolar disorder and 258 healthy volunteers. An additional independent sample set in COSMO (Collaborative Study of Mood Disorder) consisted of 431 patients with bipolar disorder and 476 healthy volunteers, was also used. To examine whether there is a hidden population structure, we performed stratification analysis on the initial samples using eight polymorphisms [3] using the method of Pritchard et al. [23], and no subpopulation was found for either patients or controls. We performed a similar stratification analysis using 20 SNPs in 169 Japanese samples, including COSMO samples, and found no subpopulation. We further analyzed the stratification in 169 Japanese samples using 374 microsatellite

markers and found no hidden subpopulation (Yamada et al., manuscript in preparation). Thus, we concluded that there is no hidden subpopulation in our Japanese samples. Six patients examined for the entire mtDNA sequence were included in the first sample set, because they developed comorbid somatic symptoms after the diagnosis of bipolar disorder.

We genotyped at 3644 and 13928 by PCR-RFLP in the initial sample set (Table 2). Base 3644C was found in 5 of 199 Japanese patients with bipolar disorder in the first sample set, including the proband (case 5 in Table 1, II-1 of family A in Fig. 1), but in none of the controls ($p = 0.015$) (Table 2). Among other 4 patients, 1 had non-insulin-dependent diabetes mellitus (NIDDM), 1 had headache, and 1 had tremor suggestive of neurological impairment. In their family members, only 5 of 25 members in the same maternal lineages, who were assumed to have the same genotype, 3644C, developed

Table 2
Association study using independent sample sets and haplogroups

Base at 3644:	All samples				Haplogroup D (5178A/10398G)			
	T		C	<i>p</i> value	T		C	<i>p</i> value
<i>Initial sample set</i>								
Patients	97.5%	(194)	2.5%	(5)	94.4%	(68)	5.6%	(4)
Controls	100.0%	(258)	0.0%	(0)	100.0%	(97)	0.0%	(0)
				0.015*				0.003*
<i>Independent sample set</i>								
Patients	99.1%	(427)	0.9%	(4)	98.3%	(171)	1.7%	(3)
Controls	99.8%	(475)	0.2%	(1)	100.0%	(192)	0.0%	(0)
				0.197				0.106
<i>Total sample set</i>								
Patients	98.6%	(621)	1.4%	(9)	97.2%	(239)	2.8%	(7)
Controls	99.9%	(733)	0.1%	(1)	100.0%	(289)	0.0%	(0)
				0.007*				0.004*

Each number in parentheses shows the real number of subjects. The *p* value was given by Fisher's exact test.

* Statistically significant.




Fig. 1. Pedigrees of the probands with bipolar disorder and mitochondrial 3644C mutation. Arrows indicate the probands with bipolar disorder. Closed squares and circles indicate the patients with bipolar disorder or other mental disorders as follows: D, I-2 had a psychotic disorder not otherwise specified, II-2 had schizotypal personality disorder. Their comorbidities were as follows: A, II-1 had muscle weakness, ptosis, and NIDDM (case 5 in Table 1); C, II-1, had essential tremor; D, II-1, had NIDDM; E, I-2, II-1, II-2, and III-1 had headache. To maintain the anonymity of the pedigrees, the sexes of the unaffected siblings are not shown.

bipolar disorder, of which 4 patients with 3644C had comorbid physical symptoms and one had only bipolar disorder. Mutation 3644T→C converts amino acid 113 valine in the putative third transmembrane region of ND1, the protein subunit of complex I, to alanine. This 113 valine is well conserved from *Drosophila* to 61 mammalian species. There was no difference in the frequency of 13928G→T [13 of 199 patients with bipolar disorder (6.5%) and 19 of 258 controls (7.4%), $p = 0.804$ by Fisher's exact test]. Mutation 13928G→T changes the 531 serine into isoleucine in the ND5 subunit and it was not conserved even among mammalian species.

We further analyzed 3644T→C as a candidate risk factor for bipolar disorder using the independent sample set obtained from COSMO. While 4 additional individuals having 3644C were found among the patients, only 1 of the 476 controls had 3644C. Although this difference in frequency was not statistically significant ($p = 0.197$), this is likely due to the low statistical power to detect the difference (0.29). In the analysis of total samples having higher statistical power (0.79), 3644C was significantly more common in bipolar disorder than in the controls ($p = 0.007$) (Table 2).

Since mtDNA is highly polymorphic, other polymorphisms possibly confounded the association analysis. To minimize the effects of other polymorphisms, we categorized these samples into mitochondrial DNA haplogroups and the association analysis was repeated in each haplogroup. Seven patients with 3644C were assigned to the Asian haplogroup D characterized by 5178A/10398G [22], which we reported as an anti-risk haplotype for bipolar disorder [10]. The 3644C was significantly associated with bipolar disorder in haplogroup D (Table 2). On the other hand, only 1 control subject and 2 patients with 3644C were

classified into haplogroup M characterized by 5178C/10398G, and no association was found in haplogroup M [2 of 187 patients (1.1%) and 1 of 233 controls (0.4%), $p = 0.588$].

We concluded that 3644C was associated with bipolar disorder for the following reasons: 3644T→C was associated with bipolar disorder in the initial case-control study; this substitution converts well-conserved amino acid 113 valine to alanine in ND1. A similar trend was observed in the independent samples, although there was no significant difference, possibly due to the small number of subjects replicating the association. In the analysis of the total sample set having enough statistical power to detect a difference, 3644C was significantly associated with bipolar disorder. The significant association between 3644C and bipolar disorder remained in haplogroup-matched case-control analysis.

We called 3644C a "mutation," because its frequency was very low (0.14% in 734 controls and 0.7% in 1364 total samples examined), it converted a well-conserved amino acid, and it appeared in at least two independent haplogroups. However, this mutation is not sufficient to cause bipolar disorder because 3644C was found in 1 healthy volunteer, and only 5 of 25 members in the same maternal lineages, all of whom were assumed to have 3644C, developed bipolar disorder. Among these patients, comorbidity in 4 patients with bipolar disorder was heterogeneous: 2 had NIDDM, 1 headache, and 1 tremor suggestive of neurological impairment. The other patient had only bipolar disorder. It means that 3644C cannot be a risk factor for comorbid symptoms seen in these patients but could be a risk factor for bipolar disorder, if not a causative mutation. Bipolar disorder is a multigenic disease and one type of mutation in mtDNA can cause various phenotypes. We

postulate that synergistic effects of other risk factors and 3644C could cause bipolar disorder.

Functional analyses in cybrids with 3644C

To evaluate the functional consequences of 3644T→C, we generated cell lines of the transmitochondrial hybrids, “cybrids,” using the platelets derived from the subjects. Different from heteroplasmic mutations in the regions of tRNAs and protein subunits, functional impairment associated with homoplasmic mutation has not been well established. In the case of heteroplasmic mutation, two cybrid cell lines with different nucleotides at one particular position of mtDNA could be generated and analyzed. On the other hand, in the case of homoplasmic mutation, it was impossible to identify such a pair of cell lines. To minimize the effects of other polymorphisms, we compared cybrids with 3644C with haplogroup-matched controls for functional studies. A total of 24 cybrid cell lines were obtained from the initial sample set, and 9 cybrid cell lines belonged to haplogroup D, 5178A/10398G (Table 3). Among the 9 cell lines, only 2 were from patients with 3644C (II-1 in family D and II-2 in family E, in Fig. 1) and 7 were from subjects with 3644T (3 patients with bipolar disorder and 4 controls). We could not obtain other samples with 3644C because of ethical reasons.

Mitochondrial membrane potential (MMP) was measured using JC-1, a fluorescent cationic dye, which accumulates in mitochondria and changes its emission from wavelength 527 nm (monomer) to 590 nm (aggregates) depending on the mitochondrial membrane potential, and a fluorescence-activated cell sorter (FACS), and it distinguished well the difference between control cybrids and ρ^0 206 cells lacking mtDNA: while $82.9 \pm 9.9\%$ (mean \pm SD, $N = 12$) of the cybrids from control subjects were polarized, only $13.2 \pm 7.7\%$ (mean \pm SE of three measurements) of the ρ^0 206 cells were polarized (Fig. 2, left and

right, respectively). This indicated that our measurement method is sensitive enough to detect the difference in MMP. The percentage of polarized cells was significantly decreased in cybrids with 3644C [51.7 ± 6.6 and $67.0 \pm 4.3\%$ (means \pm SE), respectively] compared with haplogroup-matched cybrids ($df = 8$, $p = 0.04$ by Mann-Whitney U test) (Table 3). There was no significant difference between cybrids of bipolar disorder and controls nor between cybrids of other haplogroups.

Subsequently, the activities of complexes I (rotenone-insensitive), III, and IV in the electron-transport chain were measured using the citrate synthase activity as the reference (Table 4). The activity of ρ^0 206 cells was measured to assess nonspecific activity. The 3644C group consisted of two cybrid cell lines. While there was no significant difference between complex III and complex IV activities ($p > 0.1$), complex I activity of the two cybrids with 3644C tended to be lower than four haplogroup-matched control cybrids ($df = 5$, $p = 0.06$ by Mann-Whitney U test). Decreased MMP could be explained by reduced complex I activity since MMP is maintained by the efflux of protons from the mitochondrial matrix, in which complex I plays an important role. MMP generated by the proton gradient is the driving force of not only ATP synthesis but also Ca^{2+} uptake across the mitochondrial inner membrane. We hypothesized that impaired mitochondrial Ca^{2+} uptake caused altered calcium signaling in bipolar disorder. Our result of decreased MMP in cybrids with 3644C supports our hypothesis.

Interestingly, the mtSNP database [22] showed that while 3644C was not found in 96 centenarians, it was found in 3.1% (3/96) of patients with Alzheimer disease and 2.0% (2/96) of patients with Parkinson disease. These findings suggested a possibility that 3644C is a risk factor common to bipolar disorder and neurodegenerative disorders, rather than a causative mutation only for bipolar disorder. If 3644C is also a risk factor for neurodegener-

Table 3
Mitochondrial membrane potential (MMP) of 24 cybrid cell lines

	N	Age	(C/B)	Gender	MMP
<i>Diagnosis</i>					
Control	12	48.0 \pm 9.2		6/6	82.9 \pm 9.9
Bipolar disorder	12	41.8 \pm 11.4		6/6	77.2 \pm 11.0
Bipolar disorder with 3644T	10	40.7 \pm 12.0		5/5	80.8 \pm 7.0
Bipolar disorder with 3644C	2	42, 53		1/1	59.4 \pm 10.9*
<i>Haplogroup</i>					
10398A–5178C–3644T	7	43.6 \pm 10.6	4/3	3/4	81.9 \pm 8.6
10398G–5178C–3644T	8	41.6 \pm 10.7	4/4	4/4	80.8 \pm 9.5
10398G–5178A–3644T	7	48.9 \pm 10.5	4/3	3/4	83.3 \pm 8.5
10398G–5178A–3644C	2	42, 53	0/2	1/1	59.4 \pm 10.9**
ρ^0 cells	1				13.21

C/B, numbers of control/bipolar disorder; gender, number of men/women. The p value was given by the Mann-Whitney U test.

* $p = 0.03$ vs 3644T, 0.08 vs controls.

** $p = 0.04$ vs 3644T, 0.03 vs all other haplogroups.




Fig. 2. Measurement of mitochondrial membrane potential using JC-1 and FACS. Vertical line, the fluorescence intensity of 590 nm, reflecting the aggregates and indicating high MMP. Horizontal line, the fluorescence intensity of 527 nm, reflecting the monomer and indicating low MMP. 10,000 cells were examined for one cell line. Representative results of one experiment each from three cell lines are shown. Left, control cybrids whose haplogroups were matched with the cybrids with 3644C; middle, cybrids with 3644C; right, p^0206 cells. While most control cybrids were polarized, having high 590/527 nm, most p^0206 cells were depolarized. The cybrids with 3644C were intermediate, having both polarized and depolarized cells.

ative disorders, the mechanism might be explained by a disruption of MMP that causes apoptosis. It is also compatible with the reduction of complex I activity in platelets or altered calcium signaling in cybrids derived from patients with Parkinson disease or Alzheimer disease [24–26]. Neuropathological studies of bipolar disorder also showed a decreased number of neurons in post-mortem brains [27,28]. It was pointed out that having bipolar disorder increases the risk of Alzheimer disease [29,30] and Parkinson disease [31]. Two mood stabilizers, lithium and valproate, are known to have antiapoptotic effects by increasing Bcl-2 [32]. These findings are also compatible with the possibility that 3644C is a risk factor common to bipolar disorder and neurodegenerative disorders.

One might have a concern that 3644C is not a risk factor for bipolar disorder but associated with physical symptoms. Although the initial patient had several physical symptoms suggestive of mitochondrial disorder such as ptosis, muscle weakness, NIDDM, and cerebral infarction, other patients carrying 3644C had no or one nonspecific comorbid symptom. Thus, the apparent association between bipolar disorder and 3644C cannot be explained by the secondary phenomenon due to physical symptoms. However, it cannot be ruled out that these patients carrying 3644C have some subtle mitochondria-related symptoms that were not clinically apparent. In fact, there are reports of patients with pathogenic mtDNA mutations such as 3243A→G who showed psychotic symptoms at first and developed mitochondrial diseases later [33,34]. It might be possible that detailed physical examinations, for example, glucose tolerance test or close neurological examinations, would reveal subtle comorbid somatic symptoms. Needless to say, we need to address whether the 3644C substitution is associated with somatic symptoms alone. In the future, it is needed to look carefully at the phenotype and the clinical course of these subjects and investigate whether 3644C is associated

with bipolar disorder or a bipolar disorder-somatic symptom subtype.

Functional impairment was reported also in the homoplasmic mutation, 1555A→G, in maternally inherited hearing loss [15,16]. The 11778A mutation of LHON, which is usually heteroplasmic but sometimes homoplasmic, was also shown to cause a modest reduction in complex I activity [35]. It was pointed out that the nuclear background potentially affects the expression of mtDNA polymorphisms [36]. Further study using cybrids with another nuclear background would be interesting. The mechanism of how the V113A amino acid substitution caused by 3644T→C in ND1 decreases complex I activity cannot be explained since the structure and function of each protein subunit are not yet well known. In particular, it remains unclear how complex I translocates protons across the mitochondrial inner membrane coupled to electron transfer. In summary, 3644T→C is a rare base substitution of mtDNA but induces modest impairment of complex I activity and becomes a risk factor for bipolar disorder.

Materials and methods

Subjects

Patients with bipolar disorder were diagnosed according to the DSM-III-R or DSM-IV criteria by at least two

Table 4
Enzyme activities of electron-transport chain of cybrids with 3644C and controls

	Control (mean ± SD), N = 4	3644C (mean ± SD), N = 2	p^0 cells	p value*
Complex I/CS	14.47 ± 5.43	7.64 ± 0.08	4.82	0.06
Complex III/CS	32.15 ± 12.78	21.12 ± 2.72	7.36	0.36
Complex IV/CS	39.74 ± 11.24	29.21 ± 6.97	0.76	0.36

* The p value was calculated using the Mann-Whitney U test.

interview sessions by two senior psychiatrists and a consensus diagnosis was made. Their family history of mental disorder was assessed by interviewing the proband and available relatives. Control subjects were recruited from the staff or students of participating institutes and their friends, who reported themselves to be healthy. Written informed consent was obtained from all subjects. This study was approved by the ethics committees of RIKEN and all participating institutes.

The study subjects for the initial association study consisted of 199 patients with bipolar disorder (143 bipolar I and 56 bipolar II, 76 male and 123 female, 49.8 years of age on average) and 258 healthy volunteers (129 male and 129 female, 33.0 years of age on average). An additional independent sample set in COSMO consisted of 431 patients with bipolar disorder (214 male and 217 female, 49.5 years of age on average) and 476 healthy volunteers (226 male and 250 female, 50.4 years of age on average).

Six patients with bipolar disorder with somatic symptoms suggestive of mitochondrial disorders were chosen from the first sample set for examination of the entire mtDNA. They had been recruited in our bipolar disorder study based on our inclusion criteria, having DSM-IV bipolar disorder by consensus diagnoses after two nonstructured interview sessions with senior psychiatrists, and exclusion criteria, having no clinically remarkable neurological diseases, head trauma, or comorbid Axis II diagnoses. Characteristics of these six subjects are listed below and summarized in the Table 1.

The transmitochondrial cybrids for the following functional analyses were generated from 24 subjects in the initial samples, including two patients with 3644C.

Case reports

Case 1, 38-year-old female, is a patient with bipolar I disorder without psychotic features. She had the first episode of mania with psychomotor agitation and confusion at age 17. At age 27, she was admitted to a hospital due to bilateral optic neuritis. She had no other symptoms suggestive of multiple sclerosis. Her optic neuritis was improved by steroid therapy, and final diagnosis was idiopathic optic neuropathy. Because she had no relatives with optic neuropathy and her symptoms were reversible, Leber disease was not considered by the attendant ophthalmologist.

Case 2 is a 61-year-old male diagnosed as having bipolar I disorder. At age 30, he had the onset of mania with mood-incongruent psychotic features. At age 60, after being discharged from a psychiatric hospital, he was admitted to a hospital due to stroke. Brain imaging revealed infarctions in the cerebellum and the brain stem. During this hospitalization, chest X-ray showed enlarged heart and he was diagnosed as idiopathic dilated cardiomyopathy. He also had renal failure. His attendant physician did not suspect mitochondrial disease.

Case 3 is a 56-year-old male diagnosed with bipolar I disorder. At age 49, he had the onset of depression characterized by depressive mood, fatigability, retardation, insomnia, and suicidal thought. At age 52, he suddenly became manic. During this manic episode, he caused a motor vehicle accident. He was admitted to a psychiatric ward for the treatment of mania. After the first admission, he had generalized tonic clonic seizures. Although electroencephalography (EEG) recording showed no signs of epilepsy, he was clinically diagnosed as having epilepsy. At age 54, he complained of swollen eyelid, and medical examination did not show any signs of renal failure. He also complained of muscle weakness and had an episode of falling down due to muscle weakness. A neurologist saw this patient and assessed that ptosis may be present but fluctuating and was not pathological. He also showed some tendency of disturbed movement of the eyes, but it was also fluctuating and he did not have diplopia. Muscle weakness was not objectively present. Based on these clinical examinations, the neurologist ruled out mitochondrial disease from differential diagnosis and judged that further investigation was not necessary. Electrocardiogram indicated supraventricular extrasystole, but it was not clinically remarkable.

Case 4 is a 46-year-old female diagnosed with bipolar I disorder. At age 24, she had the onset of mania. At age 40, she began rapid cycling. During her psychiatric hospitalization, EEG recording showed epileptic abnormality. However, she did not have any signs or symptoms of epilepsy and was not diagnosed as epileptic.

Case 5 is 57-year-old male diagnosed as having bipolar I disorder. He had the onset of a manic episode at age 50. Since his clinical representation resembled confusion caused by organic mental disorder, he received lumbar puncture by a neurologist during psychiatric hospitalization, which showed elevated cerebrospinal fluid protein levels. The neurologist also noted muscle weakness and slight ptosis on the left eyelid. However, these symptoms were improved without any treatment and his subsequent manic episodes were typical manic syndrome without any additional neurological features or psychotic features. He was finally diagnosed as having bipolar I disorder. After the onset of bipolar disorder, he was diagnosed as having non-insulin-dependent diabetes mellitus. His cranial magnetic resonance image showed multiple subcortical silent infarction.

Case 6 is a 38-year-old male having bipolar I disorder. His clinical record was published elsewhere [37]. He complained of ptosis during antipsychotic treatment. Both a neurologist and an ophthalmologist examined and diagnosed him as not having any mitochondrial disease, since his sign was transient and not clinically remarkable.

MtDNA sequencing

Total DNA was extracted from peripheral blood leukocytes by standard protocols. Entire mtDNA sequenc-

ing was performed as previously described [38] with some modifications. In short, each DNA sample was diluted to 10 µg/ml, and nested PCR was performed. PCR was initially performed to obtain two long PCR products, 6 and 11 kb of mtDNA; the second PCR was designed as a set of three overlapping fragments from the first 6-kb PCR product and six fragments from the first 11-kb PCR product. After the second PCR, the products were treated with a SeqDirect PCR Cleaning kit (Qbiogene, Carlsbad, CA, USA) according to the manufacturer's protocol. Both strands of these fragments were then sequenced with the BigDye Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA) and ABI Prism 3700 DNA sequencer (Applied Biosystems). Each mtDNA site was read at least three times, including at least once for each strand.

Genotyping

The two base substitutions of mtDNA, 3644T→C and 13928G→T, were genotyped using the PCR-RFLP method and sequencing. The enzymes and experimental conditions for the PCR-RFLP were as follows: 3644 was genotyped by primers 5'-GTAGAATGATGGCTAGGGTGACT-3' and 5'-TCTAGCCACCTCTAGCCTAGACG-3' and the restriction enzyme *TaqI* (Fermentas), 13928 by 5'-CATACTCGGATTC-TACGCTA-3', 5'-TTTAGGTAATAGCTTTTCTA-3', and *NheI* (Takara Bio, Inc., Shiga, Japan). MtDNAs 5178C→A and 10398A→G were genotyped to determine the haplogroups. Genotypes of 5178C→A and 10398A→G were examined as previously described [10].

Generation of cybrids

The 143B.TK⁻ ρ⁰206 cell line, lacking mtDNA and established by King and Attardi [39], was used for generating cybrids. Platelets of patients and controls were separated from peripheral blood and fused with ρ⁰206 cells using 40% polyethylene glycol 1500 (Sigma), as previously described [40]. We used DMEM (Gibco BRL) containing 10% FBS (fetal bovine serum; Gibco BRL), penicillin/streptomycin, pyruvate (Gibco BRL), and uridine (Sigma) as the growth medium for ρ⁰ cells. For the selection of transmitochondrial cybrid cell lines, we used DMEM containing 10% dialyzed FBS, penicillin/streptomycin, and pyruvate. After the harvest of individual cybrid cell lines, the integration of mtDNA was confirmed by Southern blot analysis using 18S ribosomal RNA repeating units as a reference [41]. The identity of the mtDNA of the cybrids with that of the donor was verified by sequencing the D loop and genotyping several polymorphisms. For Southern blot analysis, we used the ECL Labeling and Detection System according to the manufacturer's protocol (Amersham Biosciences Corp., NJ, USA). Cybrids were stored in liquid nitrogen for further experiments.

Measurement of MMP using JC-1

MMP was estimated using JC-1 (Molecular Probes, Eugene, OR) and flow cytometry. Cybrids stored in liquid nitrogen were thawed and incubated in an atmosphere of 5% CO₂ at 37°C in DMEM containing 10% FBS, penicillin/streptomycin, and pyruvate. Cells (1 × 10⁶) were trypsinized and harvested in 10 ml of DMEM containing 10% FBS, washed with PBS (phosphate-buffered saline) once, and stained with DMEM containing 5 µg/ml JC-1 for 15 min at 37°C. Cells were then washed with PBS and subjected to analysis using a FACS (Epics Elite cell sorter; Beckman Coulter, Fullerton, CA, USA) as previously described [42]. The excitation wavelength was 488 nm by argon ion laser. Emissions at 590 and 527 nm were isolated by each photomultiplier detector and 10,000 cells were measured for each experiment. The experiment was performed in triplicate for each cell line. The cells with polarized mitochondria were defined by an intensity ratio of 590 nm/527 nm above 0.2.

Activities of enzymes in the electron-transport chain

For the sample preparation of the mitochondrial fraction, each line of cybrids was amplified until the cell count was 5 × 10⁷. Cybrids were trypsinized and harvested in DMEM. After being washed once with PBS and once with isolation buffer [210 mM D-mannitol, 71 mM sucrose, 1 mM EGTA, 0.5% bovine serum albumin (fatty acid free), 5 mM Hepes, pH 7.2], the cells were suspended in 5 ml of isolation buffer. Using a chilled Dounce glass homogenizer with a loose fitting pestle, 20 passes were applied to the cell suspension on ice, which was centrifuged at 700g for 7 min at 4°C. The supernatant was centrifuged at 10,000g for 7 min at 4°C, and the mitochondrial pellet was obtained. The pellet was suspended in 250 mM sucrose, divided into aliquots, and kept at -80°C until use. Activities of complexes I, III, and IV were measured as previously described [43]. Rotenone-sensitive complex I activity was measured by the change in absorption of decylubiquinone. All samples were measured within 1 month from preparation. The activity of each complex was corrected by citrate synthase activity. All the chemical products for these assays were obtained from Sigma. We used a UVmini1240 spectrophotometer (Shimadzu, Kyoto, Japan) for this experiment.

Acknowledgments

We thank all the volunteers who participated in this study. We express our thanks to the members of the Research Resource Center at the RIKEN Brain Science Institute, especially to Mr. Miyazaki for the sequence procedure and to Mr. Ohtawa for the analysis of mitochondrial membrane potential. The 143B.TK⁻ ρ⁰206 cell line was a gift from Dr. Giuseppe Attardi to Dr. Makoto Yoneda.

References

- [1] P. Sklar, S.B. Gabriel, M.G. McInnis, P. Bennett, Y.M. Lim, G. Tsan, S. Schaffner, G. Kirov, I. Jones, M. Owen, et al., Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neurotrophic factor, *Mol. Psychiatry* 7 (2002) 579–593.
- [2] M. Neves-Pereira, E. Mundo, P. Muglia, N. King, F. Macciardi, J.L. Kennedy, The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study, *Am. J. Hum. Genet.* 71 (2002) 651–655.
- [3] C. Kakiuchi, K. Iwamoto, M. Ishiwata, M. Bundo, T. Kasahara, I. Kusumi, T. Tsujita, Y. Okazaki, S. Nanko, H. Kunugi, et al., Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder, *Nat. Genet.* 35 (2003) 171–175.
- [4] T. Kato, S. Takahashi, T. Shioiri, T. Inubushi, Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo ^{31}P and ^7Li magnetic resonance spectroscopy, *J. Affect. Disord.* 27 (1993) 53–59.
- [5] C. Konradi, M. Eaton, M.L. MacDonald, J. Walsh, F.M. Benes, S. Heckers, Molecular evidence for mitochondrial dysfunction in bipolar disorder, *Arch. Gen. Psychiatry* 61 (2004) 300–308.
- [6] G. Siciliano, A. Tessa, S. Petri, M. Mancuso, C. Bruno, G.S. Grieco, A. Malandrini, L. DeFlorio, B. Martini, A. Federico, et al., Autosomal dominant external ophthalmoplegia and bipolar affective disorder associated with a mutation in the ANTI gene, *Neuromuscul. Disord.* 13 (2003) 162–165.
- [7] J.N. Spelbrink, F.Y. Li, V. Tiranti, K. Nikali, Q.P. Yuan, M. Tariq, S. Wanrooij, N. Garrido, G. Comi, L. Morandi, et al., Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria, *Nat. Genet.* 28 (2001) 223–231.
- [8] G. Van Goethem, B. Dermaut, A. Lofgren, J.J. Martin, C. Van Broeckhoven, Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions, *Nat. Genet.* 28 (2001) 211–212.
- [9] F.J. McMahon, O.C. Stine, D.A. Meyers, S.G. Simpson, J.R. DePaulo, Patterns of maternal transmission in bipolar affective disorder, *Am. J. Hum. Genet.* 56 (1995) 1277–1286.
- [10] T. Kato, H. Kunugi, S. Nanko, N. Kato, Mitochondrial DNA polymorphisms in bipolar disorder, *J. Affect. Disord.* 62 (2001) 151–164.
- [11] F.J. McMahon, Y.S. Chen, S. Patel, J. Kokoszka, M.D. Brown, A. Torroni, J.R. DePaulo, D.C. Wallace, Mitochondrial DNA sequence diversity in bipolar affective disorder, *Am. J. Psychiatry* 157 (2000) 1058–1064.
- [12] S. Washizuka, C. Kakiuchi, K. Mori, H. Kunugi, O. Tajima, T. Akiyama, S. Nanko, T. Kato, Association of mitochondrial complex I subunit gene NDUFV2 at 18p11 with bipolar disorder, *Am. J. Med. Genet.* 120B (2003) 72–78.
- [13] S. Anderson, A.T. Bankier, B.G. Barrell, M.H. de Bruijn, A.R. Coulson, J. Drouin, I.C. Eperon, D.P. Nierlich, B.A. Roe, F. Sanger, et al., Sequence and organization of the human mitochondrial genome, *Nature* 290 (1981) 457–465.
- [14] D.C. Wallace, Mitochondrial diseases in man and mouse, *Science* 283 (1999) 1482–1488.
- [15] T.R. Prezant, J.V. Agopian, M.C. Bohlman, X. Bu, S. Oztas, W.Q. Qiu, K.S. Arnos, G.A. Cortopassi, L. Jaber, J.I. Rotter, et al., Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness, *Nat. Genet.* 4 (1993) 289–294.
- [16] M.X. Guan, N. Fischel-Ghodsian, G. Attardi, Biochemical evidence for nuclear gene involvement in phenotype of non-syndromic deafness associated with mitochondrial 12S rRNA mutation, *Hum. Mol. Genet.* 5 (1996) 963–971.
- [17] S.W. Chang, D. Zhang, H.D. Chung, H.P. Zassenhaus, The frequency of point mutations in mitochondrial DNA is elevated in the Alzheimer's brain, *Biochem. Biophys. Res. Commun.* 273 (2000) 203–208.
- [18] J.M. van der Walt, K.K. Nicodemus, E.R. Martin, W.K. Scott, M.A. Nance, R.L. Watts, J.P. Hubble, J.L. Haines, W.C. Koller, K. Lyons, et al., Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease, *Am. J. Hum. Genet.* 72 (2003) 804–811.
- [19] R.M. Andrews, I. Kubacka, P.F. Chinnery, R.N. Lightowlers, D.M. Turnbull, N. Howell, Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA, *Nat. Genet.* 23 (1999) 147.
- [20] A.M. Kogelnik, M.T. Lott, M.D. Brown, S.B. Navathe, D.C. Wallace, MITOMAP: a human mitochondrial genome database, *Nucleic Acids Res.* 24 (1996) 177–179.
- [21] A.M. Kogelnik, M.T. Lott, M.D. Brown, S.B. Navathe, D.C. Wallace, MITOMAP: a human mitochondrial genome database—1998 update, *Nucleic Acids Res.* 26 (1998) 112–115.
- [22] M. Tanaka, T. Takeyasu, N. Fuku, G. Li-Jun, M. Kurata, Mitochondrial genome single nucleotide polymorphisms and their phenotypes in the Japanese, *Ann. N. Y. Acad. Sci.* 1011 (2004) 1–20.
- [23] J.K. Pritchard, M. Stephens, P. Donnelly, Inference of population structure using multilocus genotype data, *Genetics* 155 (2000) 945–959.
- [24] Y. Aomi, C.S. Chen, K. Nakada, S. Ito, K. Isobe, H. Murakami, S.Y. Kuno, M. Tawata, R. Matsuoka, H. Mizusawa, J.-I. Hayashi, Cytoplasmic transfer of platelet mtDNA from elderly patients with Parkinson's disease to mtDNA-less HcLa cells restores complete mitochondrial respiratory function, *Biochem. Biophys. Res. Commun.* 280 (2001) 265–273.
- [25] R.H. Swerdlow, J.K. Parks, J.N. Davis II, D.S. Cassarino, P.A. Trimmer, L.J. Currie, J. Dougherty, W.S. Bridges, J.P. Bennett Jr., G.F. Wooten, W.D. Parker, Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family, *Ann. Neurol.* 44 (1998) 873–881.
- [26] J.P. Sheehan, R.H. Swerdlow, S.W. Miller, R.E. Davis, J.K. Parks, W.D. Parker, J.B. Tuttle, Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease, *J. Neurosci.* 17 (1997) 4612–4622.
- [27] M.P. Vawter, W.J. Freed, J.E. Kleinman, Neuropathology of bipolar disorder, *Biol. Psychiatry* 48 (2000) 486–504.
- [28] G. Rajkowska, Cell pathology in bipolar disorder, *Bipolar Disord.* 4 (2002) 105–116.
- [29] L.V. Kessing, E.W. Olsen, P.B. Mortensen, P.K. Andersen, Dementia in affective disorder: a case-register study, *Acta Psychiatr. Scand.* 100 (1999) 176–185.
- [30] R.C. Green, L.A. Cupples, A. Kurz, S. Auerbach, R. Go, D. Sadovnick, R. Duara, W.A. Kukull, H. Chui, T. Edeki, et al., Depression as a risk factor for Alzheimer disease: the MIRAGE Study, *Arch. Neurol.* 60 (2003) 753–759.
- [31] F.M. Nilsson, L.V. Kessing, T.G. Bolwig, Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study, *Acta Psychiatr. Scand.* 104 (2001) 380–386.
- [32] G. Chen, W.Z. Zeng, P.X. Yuan, L.D. Huang, Y.M. Jiang, Z.H. Zhao, H.K. Manji, The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS, *J. Neurochem.* 72 (1999) 879–882.
- [33] E.C. Thomeer, W.M. Verhoeven, C.J. van de Vlasakker, J.L. Klompenhouwer, Psychiatric symptoms in MELAS: a case report, *J. Neurol. Neurosurg. Psychiatry* 64 (1998) 692–693.
- [34] M. Yamazaki, H. Igarashi, M. Hamamoto, T. Miyazaki, I. Nonaka, A case of mitochondrial encephalomyopathy with schizophrenic psychosis, dementia and neuroleptic malignant syndrome, *Rinsho Shinkeigaku* 31 (1991) 1219–1223.
- [35] M.D. Brown, I.A. Trounce, A.S. Jun, J.C. Allen, D.C. Wallace, Functional analysis of lymphoblast and cybrid mitochondria containing the 3460, 11778, or 14484 Leber's hereditary optic neuropathy mitochondrial DNA mutation, *J. Biol. Chem.* 275 (2000) 39831–39836.

- [36] P.L. Roubertoux, F. Sluyter, M. Carlier, B. Marcet, F. Maarouf-Veray, C. Cherif, C. Marican, P. Arrechi, F. Godin, M. Jamon, et al., Mitochondrial DNA modifies cognition in interaction with the nuclear genome and age in mice, *Nat. Genet.* 35 (2003) 65–69.
- [37] T. Kato, Y. Takahashi, Deletion of leukocyte mitochondrial DNA in bipolar disorder, *J. Affect. Disord.* 37 (1996) 67–73.
- [38] J. Akanuma, K. Muraki, H. Komaki, I. Nonaka, Y. Goto, Two pathogenic point mutations exist in the authentic mitochondrial genome, not in the nuclear pseudogene, *J. Hum. Genet.* 45 (2000) 337–341.
- [39] M.P. King, G. Attardi, Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation, *Science* 246 (1989) 500–503.
- [40] A. Chomyn, S.T. Lai, R. Shakeley, N. Bresolin, G. Scarlato, G. Attardi, Platelet-mediated transformation of mtDNA-less human cells: analysis of phenotypic variability among clones from normal individuals—and complementation behavior of the tRNA^{Lys} mutation causing myoclonic epilepsy and ragged red fibers, *Am. J. Hum. Genet.* 54 (1994) 966–974.
- [41] I. Nishino, O. Kobayashi, Y. Goto, M. Kurihara, K. Kumagai, T. Fujita, K. Hashimoto, S. Horai, I. Nonaka, A new congenital muscular dystrophy with mitochondrial structural abnormalities, *Muscle Nerve* 21 (1998) 40–47.
- [42] A. Sawa, G.W. Wiegand, J. Cooper, R.L. Margolis, A.H. Sharp, J.F. Lawler Jr., J.T. Greenamyre, S.H. Snyder, C.A. Ross, Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization, *Nat. Med.* 5 (1999) 1194–1198.
- [43] I.A. Trounce, Y.L. Kim, A.S. Jun, D.C. Wallace, Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines, *Methods Enzymol.* 264 (1996) 484–509.

Expression of Ndr2 in the rat frontal cortex after antidepressant and electroconvulsive treatment

Kou Takahashi¹, Misa Yamada¹, Hisayuki Ohata¹, Kazutaka Momose¹, Teruhiko Higuchi², Kazuo Honda¹ and Mitsuhiko Yamada³

¹ Department of Pharmacology, Shuva University School of Pharmaceutical Sciences, Tokyo, Japan

² Musashi Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan

³ Division of Psychogeriatrics, National Institute of Mental Health, National Center of Neurology and Psychiatry, Chiba, Japan

Abstract

Although the therapeutic action of antidepressants most likely involves the regulation of serotonergic and noradrenergic signal transduction, no consensus has been reached concerning their precise molecular or cellular mechanisms of action. In the present study, we demonstrated that chronic treatment with a tricyclic antidepressant (imipramine) and a selective serotonin reuptake inhibitor (sertraline) reduced the expression of Ndr2 mRNA and protein in the rat frontal cortex. Ndr2 is a member of the N-Myc downstream-regulated genes. Interestingly, repeated ECT also significantly decreased Ndr2 expression in this region of the brain. These data suggest that Ndr2 may be a common functional molecule that is decreased after antidepressant treatment and ECT. Although, the functional role of Ndr2 in the central nervous system remains unclear, our findings suggest that Ndr2 may be associated with treatment-induced adaptive neural plasticity in the brain, a chronic target of antidepressant action. In conclusion, we have identified Ndr2 as a candidate target molecule of antidepressants and ECT.

Received 8 June 2004; Reviewed 20 July 2004; Revised 1 November 2004; Accepted 3 November 2004

Key words: Microarray, neural plasticity, pharmacogenomics, selective serotonin reuptake inhibitor.

Introduction

Antidepressants are very effective agents for preventing and treating depression and have been used clinically for more than 50 yr. Typical antidepressants significantly increase the synaptic concentration of norepinephrine and/or serotonin. However, a latency period of several weeks generally elapses before the therapeutic effects of antidepressants are observed. This delayed therapeutic action could result from either the indirect regulation of other neuronal signal transduction systems or the regulation of gene transcription following chronic treatment. Indeed, antidepressants have been shown to affect the expression of immediate early genes and transcription factors, including *c-fos*, *FosB*, *junB*, *NGF1-A*, and *CREB* (see

review by Yamada and Higuchi, 2002). These regulatory proteins activate or repress genes that encode specific proteins, and may be involved in critical steps that mediate treatment-induced alterations of central nervous system function. We recently performed expressed-sequence tag (EST) analyses to identify some biological changes observed in rat brain after chronic treatment with antidepressants (Yamada et al., 2001). We developed our original ADRG microarray for high-throughput secondary screening of these candidate genes (Yamada et al., 2000). To date, we have cloned several cDNA candidates as ESTs from the rat brain and have named these antidepressant-related genes (ADRGs).

While antidepressant pharmaceuticals have been shown to be an effective treatment, another important therapy that is widely used for treating depression is repeated electroconvulsive treatment (ECT). Because of its safety, high efficacy, and rapid onset of action, ECT is well-suited for treating patients with severe psychotic depression, severe depression with suicidal ideation, drug-resistant depression, and for treating

Address for correspondence: M. Yamada, M.D., Ph.D., Division of Psychogeriatrics, National Institute of Mental Health, National Center of Neurology and Psychiatry, 1-7-3 Kohnodai, Ichikawa, Chiba 272-0827, Japan.
Tel.: +81-47-375-4742 (ext. 1270) Fax: +81-47-375-4795
E-mail: mitsu@ncnp-k.go.jp




Figure 1. Image analysis of ADRG microarray after hybridization with fluorescent probes. Ninety-six spots representing ADRG97–192 are shown. (a) Merged pseudo-colour image of control group data (green) and chronic sertraline treatment group (red). As expected, we obtained low background and consistent results in duplicate experiments. (b) Merged pseudo-colour image of control group data (green) and repeated ECT group data (red). Blue rectangle demarcates ADRG123 (Ndr2). Interestingly, the fluorescence intensities of the spots increased 0.63-fold in the sertraline group and 0.49-fold in the ECT group compared to controls.

geriatric patients and others with medical illnesses that contraindicate the use of antidepressants. Although ECT is an effective treatment for depression, the basis for its therapeutic mechanism remains unknown. An increasingly popular working hypothesis is that both antidepressants and ECT have therapeutic effects because they share some final common pathway regulating transcription of the same set of downstream genes. Indeed, we have recently reported that VAMP2 (Yamada et al., 2002) and kf-1 (Nishioka et al., 2003; Yamada et al., 2000) are expressed both after chronic antidepressant drug treatment and repeated ECT.

In the present study, we identified ADRG123 as rat Ndr2 (Swiss-Prot/TrEMBL accession numbers Q8VBU2, Q8VI01). Ndr2 is highly related to N-Myc downstream-regulated protein 1 (Ndr1), which has been linked to stress responses, cell proliferation, and differentiation, although Ndr2 itself is not repressed by N-Myc (Okuda and Kondoh, 1999). Thus far, four different isoforms of rat Ndr2 have been identified (Figure 1; Boulkroun et al., 2002). The 5' untranslated region (5' -UTR) for Ndr2a1/Ndr2a2 is 87 bp, whereas the 5' -UTR for Ndr2b1/Ndr2b2 is 50 bp. In the translated region, Ndr2a1/Ndr2b1 has an additional 42 bp insertion compared to Ndr2a2/Ndr2b2. Here, we denote Ndr2a1/Ndr2b1 and Ndr2a2/Ndr2b2 to represent Ndr2L and Ndr2S respectively. Comparison and alignment of amino-acid sequences indicated that Ndr2L is longer than Ndr2S by 14 amino acids and that both isoforms share the characteristic Ndr family sequence. Here,

we provide the first report that chronic antidepressant drug treatment and repeated ECT decreases the expression of Ndr2 mRNA and protein in the rat frontal cortex.

Materials and methods

Experimental animals and treatments

Male Sprague–Dawley rats (age 7–10 wk, Sankyo Labo Service Co., Tokyo, Japan) were housed in a temperature-controlled environment with a 12 h light/12 h dark cycle and were given free access to food and water. Rats were randomly separated into control and treated groups. Imipramine (Sigma-Aldrich, Inc., MO, USA) and sertraline (Pfizer Pharmaceuticals Inc., NY, USA) were dissolved in 1.5% Tween-80. For the chronic antidepressant-treatment group, rats received daily intraperitoneal injections of vehicle, 10 mg/kg of imipramine, or 10 mg/kg sertraline for 21 d. For the ECT group, rats were anaesthetized with sevoflurane, then given either a single electric shock (90 mA, 1.0-s duration) via ear-clip electrodes (single-dose ECT group) or electric shocks (90 mA, 1.0-s duration) every other day for 14 d (repeated ECT group). ECT was delivered with a Ugo Basile Model 7801 unipolar square-wave electroconvulsive stimulation pulse generator (Stoelting Co., IL, USA). Control rats were treated exactly like the ECT-treated rats but did not receive any electric current.

Twenty-four hours after the final antidepressant or ECT treatment, animals were euthanized by

COLOUR

AQ1

AQ4

AQ4

decapitation. The brain was quickly removed, dissected, and immediately frozen in liquid nitrogen and stored at -80°C until later use. All animal studies were carried out in accordance with National Institutes of Health guidelines in line with the OPRR Public Health Service Policy on Humane Care and Use of Laboratory Animals.

Identification of Ndr2 by ADRG microarray

Fabrication of the ADRG microarray and fluorescence image analysis was done as described previously (Yamada et al., 2000). Briefly, each of the ADRG cDNA inserts was amplified by vector primers and negative controls, and 10 different kinds of housekeeping genes were spotted in duplicate onto glass slides with a GMS417 Arrayer (Affymetrix Inc., CA, USA). Hybridization of fluorescent probes to the microarray was done competitively and in duplicate. After hybridization and washing, each slide was scanned with a GMS418 Array Scanner (Affymetrix Inc.). Gene expression levels were quantified and analysed with ImaGene software (Bio-Discovery Ltd, Swansea, UK). Preliminary assessment of the arrays (data not shown) indicated that the differences in fluorescence intensities (± 2 -fold) were significant. Sequence analysis of ADRG123 was performed by dideoxy sequencing methods. Homology search and sequence alignment was done using the FASTA search servers at the National Center for Biotechnology Information.

Expression analysis by real-time quantitative PCR

As described above, rat Ndr2 protein consists of two splice variants, Ndr2S and Ndr2L. However, we previously demonstrated using conventional RT-PCR analyses that transcript processing into long and short forms of Ndr2 does not appear to be significantly regulated after antidepressant treatments (data not shown). Therefore, we performed mRNA expression analysis of Ndr2 with real-time quantitative PCR; total levels of Ndr2S and Ndr2L mRNA were examined in the present study.

Total RNA was extracted from samples using Isogen reagent (Nippon Gene Co., Tokyo, Japan) according to the manufacturer's instructions. Total RNA samples treated with RNase-free DNase I were used to synthesize the first strand cDNA via reverse transcriptase and oligo-dT primer. We quantified Ndr2 expression in the rat frontal cortex with real-time quantitative PCR using an ABI PRISM 7000 instrument (Applied Biosystems, Foster City, CA, USA). PCR primers were designed using Primer Express Software (Applied Biosystems). A quantity of

cDNA corresponding to 20 pg of total RNA was amplified by PCR in duplicate. For each sample, three distinct amplifications were carried out in parallel. The following primers were used for rat Ndr2 (5'-AACTTTGAGCGAGGTGGTGAGA-3' and 5'-ATTCCACCACGGCATCTTCA-3') and β -actin (5'-TCGCTGACAGGATGCAGAAGG-3' and 5'-GCCAGGATAGAGCCACCAAT-3'). The SYBR[®] Green PCR Core Reagents kit (Applied Biosystems) was utilized for fluorescence detection of cDNA. For quantification, we used the Standard Curve Method (User Bulletin, ABI PRISM 7000 Sequence Detection System). Briefly, for rat Ndr2 and β -actin, an absolute standard curve was obtained by plotting the threshold cycle following PCR amplification of serial dilutions of control cDNA template.

Expression analysis by Western blotting

Anti-rat-Ndr2 antiserum was prepared as follows. Synthetic rat Ndr2 peptides (CSL TSAASIDGSRSR, RDLNFERGGEMTLKC, and CEVQITEEKPLLPQG) were coupled to activated keyhole limpet haemocyanin using *m*-maleimidobenzoyl-*N*-hydroxysuccinimide ester, then injected into Hartley guinea pigs (Takara). Immune serum was then collected and used for Western blot analysis and immunohistochemistry.

Frontal cortices from control and treated rats were homogenized in ice-cold sucrose-Tris buffer (250 mM sucrose, 50 mM Tris-HCl, 5 mM EDTA, 10 mM EGTA, 0.3% mercaptoethanol; pH 7.4). Three rats were used for each treatment group. The protein concentration was determined by the Bradford method and a Bio-Rad protein assay kit. Each fraction (20 μg protein) was separated by 7.5% SDS-PAGE after solubilization and boiling in Laemmli buffer. Electrophoretically separated proteins were transferred from gels onto nitrocellulose membranes via standard techniques. To examine the expression of Ndr2 in HEK293 cells overexpressing rat Ndr2S and Ndr2L respectively, Western blot analyses were performed on protein extracts derived from the transfected cells. Pre-immune serum was used as negative control.

Non-specific immunostaining was blocked by incubating the membranes in blocking buffer comprised of 5% skim milk. The membranes were sequentially incubated in blocking buffer with anti-rat-Ndr2 antiserum (1:500), followed by HRP-conjugated goat anti-guinea pig antibody (1:2000; ICN Biomedicals Inc., CA, USA). Immunoreactive bands were visualized on film via the ECL system. To ensure the fidelity of this analysis, we assayed only film exposed in the linear

range. The optical density of the digitized bands was quantified using NIH Image. NIH Image is a public domain program (developed at the U.S. National Institutes of Health and available on the Internet at <http://rsb.info.nih.gov/nih-image/>).

Phosphatase digestion

For the phosphatase digestion study, a protein sample from the rat frontal cortex was incubated with lambda protein phosphatase, a Mn^{2+} -dependent protein phosphatase that acts on phosphorylated serine, threonine, and tyrosine residues. The protein aliquot was incubated for 1 h at 30 °C in 50 μ l of lambda-protein phosphatase reaction buffer [50 mM Tris-HCl (pH 7.5), 5 mM dithiothreitol, 0.1 mM Na_2EDTA , 0.01% Brij 35, and 2 mM $MnCl_2$] with or without 1 μ l lambda-protein phosphatase (400 000 U/ml; New England Biolabs Inc., USA). The proteins were then analysed by Western blot together with an identically treated aliquot incubated without phosphatase.

AQ4

Cell culture and transfection of *Ndr2S* and *Ndr2L* in HEK293 cells

HEK293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich) supplemented with 10% fetal calf serum, 0.1 mM MEM non-essential amino-acid solution (Invitrogen, CA, USA), 100 U/ml penicillin, and 100 μ g/ml streptomycin (Invitrogen) at 37 °C in a humidified atmosphere comprised of 5% CO_2 .

AQ4

The coding regions for *Ndr2S* and *Ndr2L* were obtained by RT-PCR of rat brain mRNA with the following set of primers: 5'-CTCGAGGCCACCATGGCAGAGC-3', 5'-GAATTCTCTCAACAGGAGACTCCATGGTG-3' and high fidelity Platinum pfx DNA polymerase (Invitrogen). These primers contain either *Xho*I or *Eco*RI sites (underlined) to facilitate subcloning. Each of the PCR products were then ligated into pCR II-TOPO vectors (Invitrogen) and transformed into competent DH5 α *E. coli* cells. The resulting plasmid vectors were subcloned into pIRES-EGFP (Clontech, CA, USA) for transfection. In this study, we used the pIRES-EGFP vector, which can express GFP and target molecules separately. HEK293 cells were then transfected with 3 μ g of recombinant plasmid in serum-free medium using 4 μ l Lipofectamine reagent (Invitrogen) according to the manufacturer's instructions.

AQ4

Immunohistochemistry

Rats were anaesthetized with sodium pentobarbital and transcardially perfused with 4%

paraformaldehyde (Sigma-Aldrich) in 0.1 M phosphate buffer (pH 7.4). The brains were then cryoprotected and quickly frozen. The brain was sectioned (40 μ m) using a cryostat CM-501 (Sakura, Tokyo, Japan), and floating sections were further fixed with 4% paraformaldehyde overnight. Sections were boiled in phosphate buffer containing 0.9% NaCl (PBS) for 1 h, permeabilized with 0.1% Triton X-100 in PBS (PBST) for 20 min, and then blocked with PBS containing 1.5% normal goat serum for 20 min. Sections were incubated with anti-rat-*Ndr2* antiserum (1:500) in PBST for 24 h at 4 °C, washed three times with PBST, and incubated with biotinylated anti-guinea pig antibody (1:250, Vector Laboratories, CA, USA) for 30 min at room temperature. Sections were washed three times with PBST, treated with 0.3% hydrogen peroxide for 30 min, washed three times with PBST again, and incubated with avidin-biotin peroxidase complex (Vector Laboratories) for 30 min. Visualization of the peroxidase was performed with 0.01% hydrogen peroxide and 0.01% diaminobenzidine as a chromogen. The slides were counterstained with haematoxylin and analysed with an Olympus BX-60 light microscope (Olympus Optical, Tokyo, Japan).

AQ4

Statistical analysis

Data are presented as means \pm s.e.m. for each group. For antidepressant or ECT experiments, differences were assessed using analysis of variance (ANOVA) followed by the Dunnett's test. A value of $p < 0.05$ was regarded as significant.

Results

Identification of *Ndr2* as ADRG123

Figure 1 shows a pseudo-colour image of the ADRG microarray after hybridization with frontal cortex samples obtained from sertraline- or ECT-treated rats. As expected, we obtained low background and consistent results in duplicate experiments. After normalization of the signals with both negative and positive controls, fluorescence intensities representing ADRG123 decreased 0.63-fold in the sertraline group and 0.49-fold in the ECT group. These data were reproducible and inter-assay variability was negligible. As shown in Figure 2, the ADRG123 fragment obtained from the initial EST analysis was 230 bp (starting at the 3'-end containing poly-A⁺ sequences). Homology search of the EMBL/GeneBank database revealed that ADRG123 perfectly matches the full-length cDNA sequence of the rat *Ndr2* gene (Swiss-Prot/TrEMBL accession numbers Q8VBU2, Q8VI01).